NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
iBio, Inc. IBIO
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$400,000
▲ 77.8% vs FY2023
EPS · FY24
$-1.75
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-101.5%
Net margin · FY24
-4594.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 400,000.00
Revenue, FY2024 · full 15-year series below
Revenue
Net income
The company lost 4594 cents on every revenue dollar this year.
Per share
USD -1.75
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-101.5%
Return on equity, FY2024
ROE
Operating margin-4650.5%
Net margin-4594.2%
Return on assets-70.8%
Each USD of equity lost 102 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−24.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−40.3%
−24.6%
−14.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2024
Change, 5 years+175.2%
Change, 10 years—
The share count grew 175% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 23.2M
total assets, end of FY2024
Total assetsUSD 23.2M
EquityUSD 14.9M
CashUSD 8.6M
Current ratio1.59×
Equity funds 64% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.75
−6.50
−106.19
−5.78
−3.00
−0.61
−0.94
−1.54
−1.64
−0.12
−0.09
−0.06
−0.13
−0.14
−0.39
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−101.5
−135.7
−164.9
−58.5
−28.1
−55.6
−188.9
−128.4
−154.2
−92.3
−76.5
−65.7
−110.3
−178.4
−1909.0
Shares out B
0.02
0.01
0.00
0.01
0.00
0.00
0.02
0.02
0.01
0.09
0.08
0.07
0.06
0.05
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed